Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose pharmacokinetics of Riluzole (XRP4274) and metabolite RPR112512 in healthy males
2004-002390-23Phase 4Completed
- Sponsor
- Sanofi
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of riluzole in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Sanofi. Primary endpoints: Cmax of riluzole in plasma, AUC of riluzole in plasma and 9 more. Started Nov 2004; status: completed.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2004-002390-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002390-23.